CORCEPT THERAPEUTICS INC (CORT) Stock Overview
USA - NASDAQ:CORT - US2183521028 - Common Stock
CORT Key Statistics, Chart & Performance
The current stock price of CORT is 80 USD. In the past month the price increased by 13.75%. In the past year, price increased by 82.11%.
CORT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.75 | 714.53B | ||
| JNJ | JOHNSON & JOHNSON | 17.42 | 419.56B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 15.45 | 269.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 17.45 | 240.29B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.94 | 238.81B | ||
| MRK | MERCK & CO. INC. | 10.44 | 200.82B | ||
| PFE | PFIZER INC | 7.09 | 136.68B | ||
| SNY | SANOFI-ADR | 10.56 | 114.66B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.68 | 91.55B | ||
| GSK | GSK PLC-SPON ADR | 9.05 | 82.42B | ||
| ZTS | ZOETIS INC | 23.26 | 64.11B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.76 | 47.40B |
Related stock screener links
About CORT
Company Profile
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company is headquartered in Redwood City, California and currently employs 500 full-time employees. The company went IPO on 2004-04-15. The firm is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The firm operates through the discovery, development and commercialization of the pharmaceutical products segment. The firm has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Company Info
CORCEPT THERAPEUTICS INC
101 Redwood Shores Parkway
Redwood City CALIFORNIA 94025 US
CEO: Joseph K. Belanoff
Employees: 500
Phone: 16506888803
CORCEPT THERAPEUTICS INC / CORT FAQ
What is the stock price of CORCEPT THERAPEUTICS INC today?
The current stock price of CORT is 80 USD. The price decreased by -0.65% in the last trading session.
What is the ticker symbol for CORCEPT THERAPEUTICS INC stock?
The exchange symbol of CORCEPT THERAPEUTICS INC is CORT and it is listed on the Nasdaq exchange.
On which exchange is CORT stock listed?
CORT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CORCEPT THERAPEUTICS INC stock?
10 analysts have analysed CORT and the average price target is 137.96 USD. This implies a price increase of 72.44% is expected in the next year compared to the current price of 80. Check the CORCEPT THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CORCEPT THERAPEUTICS INC worth?
CORCEPT THERAPEUTICS INC (CORT) has a market capitalization of 8.43B USD. This makes CORT a Mid Cap stock.
How many employees does CORCEPT THERAPEUTICS INC have?
CORCEPT THERAPEUTICS INC (CORT) currently has 500 employees.
What are the support and resistance levels for CORCEPT THERAPEUTICS INC (CORT) stock?
CORCEPT THERAPEUTICS INC (CORT) has a support level at 73.26 and a resistance level at 80.52. Check the full technical report for a detailed analysis of CORT support and resistance levels.
Is CORCEPT THERAPEUTICS INC (CORT) expected to grow?
The Revenue of CORCEPT THERAPEUTICS INC (CORT) is expected to grow by 24.95% in the next year. Check the estimates tab for more information on the CORT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CORCEPT THERAPEUTICS INC (CORT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CORT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CORT, evaluating the profitability, health, valuation and growth aspects
- CORCEPT THERAPEUTICS INC (CORT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CORCEPT THERAPEUTICS INC (CORT) Sales and EPS estimates to see what analysts future expectations are.
- CORCEPT THERAPEUTICS INC (CORT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CORCEPT THERAPEUTICS INC (CORT) Insider and Institutional Ownership to learn about the owners and their transactions.
- CORCEPT THERAPEUTICS INC (CORT) Stock Chart to make your own analysis
- CORCEPT THERAPEUTICS INC (CORT) Latest news and press-releases to stay up to date.
Does CORCEPT THERAPEUTICS INC (CORT) stock pay dividends?
CORT does not pay a dividend.
When does CORCEPT THERAPEUTICS INC (CORT) report earnings?
CORCEPT THERAPEUTICS INC (CORT) will report earnings on 2025-10-28, after the market close.
What is the Price/Earnings (PE) ratio of CORCEPT THERAPEUTICS INC (CORT)?
The PE ratio for CORCEPT THERAPEUTICS INC (CORT) is 70.8. This is based on the reported non-GAAP earnings per share of 1.13 and the current share price of 80 USD. Check the full fundamental report for a full analysis of the valuation metrics for CORT.
What is the Short Interest ratio of CORCEPT THERAPEUTICS INC (CORT) stock?
The outstanding short interest for CORCEPT THERAPEUTICS INC (CORT) is 11.68% of its float. Check the ownership tab for more information on the CORT short interest.
CORT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CORT. When comparing the yearly performance of all stocks, CORT is one of the better performing stocks in the market, outperforming 90.33% of all stocks.
CORT Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to CORT. CORT has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
CORT Financial Highlights
Over the last trailing twelve months CORT reported a non-GAAP Earnings per Share(EPS) of 1.13. The EPS decreased by 0% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 18.66% | ||
| ROA | 16.67% | ||
| ROE | 21.02% | ||
| Debt/Equity | 0 |
CORT Forecast & Estimates
10 analysts have analysed CORT and the average price target is 137.96 USD. This implies a price increase of 72.44% is expected in the next year compared to the current price of 80.
For the next year, analysts expect an EPS growth of -1.91% and a revenue growth 24.95% for CORT